GFC Life Science Co., Ltd.
KKRX:3886104,620.00
KRW
0.00
(0.00%)
ISIN
KR7388610008
Return %
Stock
S&P 500
1Y
-74.96
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Hee-Cheol Kang
- Full Time Employees
- 86
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Hwaseong-si South Korea
- IPO Date
- Dec 23, 2022
- Website
- gfcos.co.kr
- Similar Companies
- Business
- GFC Life Science Co., Ltd. is a South Korea-based biotechnology and cosmetic ingredients company that develops, manufactures, and commercializes bio-active materials, medical aesthetic solutions, and skin clinical evaluation services. Founded in 2002 and headquartered in Hwaseong-si, Gyeonggi-do, South Korea, the company operates across three primary business divisions: Cosmetic Bio-Materials, Medical Aesthetics and Devices, and Clinical Efficacy Testing. In its Cosmetic Bio-Materials division, the company specializes in active cosmetic raw materials developed through proprietary plant cell culture, skin microbiome strains, and exosome isolation platforms including Hybrid-Exotech™; plant callus and botanical stem cell extracts; milk- and lactic acid bacteria-derived exosome complexes; and functional natural extracts engineered for anti-aging, skin barrier restoration, hydration, and brightening applications. In its Medical Aesthetics and Device division, the company manufactures and sells aesthetic treatments under its proprietary brand GFCCELL, comprising specialized exosome-based skin boosters including EXO VITAL, EXO GLOW, EXO PN with salmon-derived polynucleotides, and EXO SCALP; GFCCELL Luxe Filler hyaluronic acid dermal fillers; and regulated medical devices including Class 1 non-sterile medical gels and Class 2 topical hydrogel wound dressings. Through its Clinical Research division, which incorporates the merged Korea Dermatology Research Institute, the company provides in vivo human clinical trials, safety evaluations, and efficacy verification testing for cosmetic formulations, cosmeceuticals, and personal care products to substantiate regulatory and marketing claims. GFC Life Science distributes its raw materials, finished formulations, and OEM/ODM products to domestic dermatology clinics, medical aesthetics centers, and multinational cosmetics manufacturers across South Korea, broader Asia, Europe, and the Middle East. Recent major corporate developments include the transfer listing of the company's shares from the KONEX market to the KOSDAQ market of the Korea Exchange (KRX: 388610) in June 2025; the establishment of certified medical device manufacturing infrastructure at its Dongtan headquarters to accelerate the production of wound care hydrogels and medical aesthetic formulations; the commercial introduction and global rollout of the GFCCELL aesthetic portfolio, including exosome skin boosters and hyaluronic acid fillers; the acquisition of European Cosmetic Products Notification Portal (CPNP) certifications to expand its distribution footprint in the European Union; and the execution of strategic ingredient licensing and commercialization agreements, including exclusive supply arrangements for proprietary milk-derived exosome materials.